Agenus Inc (NASDAQ:AGEN) – Equities research analysts at William Blair lifted their FY2020 earnings per share estimates for shares of Agenus in a report issued on Monday, October 15th, according to Zacks Investment Research. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($1.44) per share for the year, up from their previous estimate of ($1.59).
Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The company had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $10.76 million.
Shares of AGEN stock traded down $0.08 during mid-day trading on Thursday, hitting $1.99. 712,918 shares of the stock were exchanged, compared to its average volume of 1,305,321. Agenus has a 52-week low of $1.54 and a 52-week high of $6.19. The firm has a market cap of $234.49 million, a P/E ratio of -1.62 and a beta of 2.19.
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Agenus by 15.7% during the 2nd quarter. BlackRock Inc. now owns 5,717,966 shares of the biotechnology company’s stock worth $12,980,000 after acquiring an additional 776,715 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Agenus during the 1st quarter worth about $197,000. UBS Group AG raised its position in shares of Agenus by 1,180.3% during the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 126,684 shares during the last quarter. RTW Investments LP raised its position in shares of Agenus by 0.7% during the 2nd quarter. RTW Investments LP now owns 9,375,451 shares of the biotechnology company’s stock worth $21,282,000 after purchasing an additional 61,895 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its position in shares of Agenus by 6.3% during the 1st quarter. Allianz Asset Management GmbH now owns 245,965 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 14,634 shares during the last quarter. 35.29% of the stock is currently owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Story: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.